AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi's Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product.
AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi's Dupixent.
An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi's Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product.
Open the app view to save this story, compare related coverage, and continue from the same source.